NuCana PLC Sponsored ADR (NASDAQ:NCNA – Get Free Report) shares were up 1.6% during mid-day trading on Monday . The stock traded as high as $3.73 and last traded at $3.70. Approximately 80,665 shares were traded during trading, an increase of 47% from the average daily volume of 54,906 shares. The stock had previously closed at $3.64.
Analysts Set New Price Targets
NCNA has been the subject of several research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of NuCana in a research report on Wednesday, October 8th. Wall Street Zen raised NuCana from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, NuCana currently has an average rating of “Sell”.
Check Out Our Latest Research Report on NCNA
NuCana Price Performance
NuCana (NASDAQ:NCNA – Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($2.69) by $2.59. Analysts forecast that NuCana PLC Sponsored ADR will post -13.42 earnings per share for the current year.
About NuCana
NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.
At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.
Featured Stories
- Five stocks we like better than NuCana
- A month before the crash
- How a Family Trust May Be Able To Help Preserve Your Wealth
- BNZI: BNZI Surges Ahead as AI Marketing Fuels Record Revenue
- A U.S. “birthright” claim worth trillions – activated quietly
- A Message From An Ex-CIA Officer About Trump
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.
